Digital Strategies to Accelerate Modern Biopharmaceutical Process Development

In this stimulating webinar, gain insights into overcoming the challenges of biopharmaceutical process development, simplifying digital strategies for cell line development, upstream and downstream processing and analytical operations in modern drug modalities.

Process development has evolved considerably to support the biopharma shift towards newer drug modalities and accelerated development pathways. However, the software applications available to process development teams remain a siloed array of rigid point solutions, legacy electronic lab notebook (ELN) and laboratory information management system (LIMS) applications, custom integrations and internally built systems. These software applications contribute to siloed data, poor user experience and high cost of ownership. A new digital approach is required for process teams to thrive in the modern era of biopharmaceutical development.

In this session, the attendees will learn key digital strategies to improve process design for cutting-edge therapies, plan better experiments, unify process data and simplify technology transfer. The featured speakers will cover digital strategies for cell line development, upstream and downstream processing and analytical operations.

Join this webinar to gain insights into implementing strategies in technology transfer and biopharmaceutical process development to drive innovation in modern drug modalities.

Speakers

Areef Jetha, Market Strategy Lead — Development, Benchling

Areef Jetha is Market Strategy Lead for Development at Benchling, where he works at the intersection of product, market and customer needs. Previously, he was an Associate Partner at McKinsey where he led strategy consulting engagements for a range of industry leaders. He received his MBA from INSEAD and his BS from the University of Cambridge.

Message Presenter

Justin De La Cruz, Solutions Consultant, Benchling

Justin De La Cruz is a Solutions Consultant at Benchling. He supports customers on bioprocess development use cases by developing best-practice solution assets that drive successful transformations.

Prior to Benchling, he spent 8+ years leading analytical method development and quality control for multiple AAV-based gene therapy programs. He earned his Ph.D. in Microbiology and Immunology at UCLA and completed his post-doctoral fellowship in Infectious Diseases at Stanford University.

Message Presenter